



Euploidia x Dose FSH

Edson Borges Jr.

Fertility Medical Group

Instituto Sapientiae

DELARO:

Ausência de Conflito de Interesse

**Resolução do Conselho Federal de Medicina
nº 1.595/2.000**

Euploidia x Dose FSH

O que diz a literatura?





Research Article

A Higher Ovarian Response after Stimulation for IVF Is Related to a Higher Number of Euploid Embryos

Elena Labarta,¹ Ernesto Bosch,¹ Amparo Mercader,² Pilar Alamá,¹
Emilia Mateu,² and Antonio Pellicer¹

¹Human Reproduction Unit, Instituto Valenciano de Infertilidad (IVI), Plaza de la Policía Local 3, 46015 Valencia, Spain

²PGD Laboratory, Instituto Valenciano de Infertilidad (IVI), Plaza de la Policía Local 3, 46015 Valencia, Spain



Aneuploidy rate did not increase with ovarian response or gonadotropin doses

Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women

Qianqian Wu^{1,2,3,†}, Hongchang Li^{1,2,3,†}, Yueting Zhu^{1,2,3},
Wenjie Jiang^{1,2,3}, Juanjuan Lu^{1,2,3}, Daimin Wei^{1,2,3}, Junhao Yan^{1,2,3,*},
and Zi-Jiang Chen^{1,2,3,4,5}

- ❑ In the group of younger women (<35 y.o., 537 PGS cycles), the incidence of aneuploidy ranged from 36.9 to 43.4% when data was stratified by gonadotropins dose. After adjusting for confounding factors, *the dose of exogenous gonadotropins was not associated with the blastocyst aneuploidy rate*;
- ❑ Similar results were shown in the group of women with advanced maternal age (≥35 y.o., 551 PGS cycles), with *no difference in the rate of blastocyst aneuploidy among different gonadotropins dose groups* (<1500 IU, 58.0%; 1500–3000 IU, 59.8%; and >3000 IU, 59.8%; $P = 0.86$).




Figure 1 Association between gonadotropins dosage and aneuploidy rates. Based on the numbers before adjustment for confounding factors.

High Gonadotropin Dosage Does Not Affect Euploidy and Pregnancy Rates in IVF PGS Cycles With Single Embryo Transfer

Oleksii O. Barash, Mary D. Hinckley, Evan M. Rosenbluth,
Kristen A. Ivani, and Louis N. Weckstein

Reproductive Science Center of the San Francisco Bay Area, San Ramon, CA

Hum Reprod 2017;32:2209–2217

- ❑ No significant difference was found in euploidy *rates regardless of the total dosage of gonadotropins used* or the number of eggs retrieved.
- ❑ *In patients younger than 35 years* (187 IVF cycles), euploidy rates ranged from 62.3% (when <3000 IU was used in the IVF cycle) to 67.5% (when >5000 IU was used in the IVF cycle; odds ratio [OR], 0.862; 95% confidence interval [CI], 0.687–1.082; $P = 0.2$).
- ❑ Similar data were obtained in patients of *advanced maternal age* (≥ 41 years of age, 189 IVF cycles). When this age group was analyzed by total dosage of gonadotropins used in the IVF cycle, euploidy rates ranged from 30.7% to 26.4% (*OR, 0.811; 95% CI, 0.452–1.454; $P = 0.481$*)



FERTILITY

No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12 298 trophectoderm biopsies

M. Irani^{1,*}, C. Canon², A. Robles², B. Maddy³, V. Gunnala¹, X. Qin¹,
C. Zhang¹, K. Xu¹, and Z. Rosenwaks¹

¹The Ronald O. Perleman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, NY 10021, USA,
²Obstetrics and Gynecology, New York Presbyterian/Weill Cornell Medicine, New York, NY 10021, USA, ³Weill Cornell Medicine,
New York, NY 10021, USA

- Within the same age group, *both euploidy rates and LBRs were comparable between cycles regardless of their differences in total gonadotropin dosage, duration of stimulation*, number of oocytes harvested, size of the largest follicles or peak estradiol levels.
- *In the youngest group*, (<35 years, $n=3469$ embryos), *euploidy rates were comparable between cycles with various total gonadotropin dosages (55.6% for <4000 IU, 52.9% for 4000–6000 IU and 62.3% for >6000 IU; $P=0.3$*
- Similarly, *in the oldest group* (>42 years, $n=1157$ embryos), *euploidy rates ranged from 8.7% for gonadotropins <4000 IU to 5.1% for gonadotropins >6000 IU ($P=0.3$)*

The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response

Lucky Sekhon^{1,2} • Kathryn Shaia¹ • Anthony Santistevan³ • Karen Hunter Cohn³ • Joseph A. Lee² • Piraye Yurttas Beim³ • Alan B. Copperman^{1,2}

Received: 11 November 2016 / Accepted: 8 March 2017
© Springer Science+Business Media New York 2017

- ☐ The degree of exposure to exogenous gonadotropins *did not significantly modify the likelihood of aneuploidy in patients with a normal ovarian response to stimulation* (not requiring COH beyond cycle day 12).
- ☐ Patients *requiring prolonged COH were demonstrated to have elevated odds of aneuploidy* with increasing cumulative gonadotropin dose.

This finding may reflect an increased tendency towards oocyte and embryonic aneuploidy in patients with a diminished response to gonadotropin stimulation

CLINICAL: RESEARCH COMMUNICATION



Effect of ovarian stimulation on embryo aneuploidy and mosaicism rate

Alba Cascales^a, Belen Lledó ^a, Jose A. Ortiz^a, Ruth Morales^a, Jorge Ten ^b, Joaquin Llácer^c,
and Rafael Bernabeu^c

^aMolecular Biology Department, Instituto Bernabeu, Alicante, Spain; ^bReproductive Biology, Instituto Bernabeu, Alicante, Spain;

^cReproductive Medicine, Instituto Bernabeu, Alicante, Spain

- ❑ The embryo aneuploidy rate showed no association with the use of oral contraceptives, type, *total and daily doses of gonadotropins, stimulation protocol type*, and drugs used for ovulation trigger ($p > 0.05$).
- ❑ In contrast, the duration of the ovarian stimulation treatment was correlated with the aneuploidy rate: patients requiring more days of stimulation presented a lower rate of aneuploid embryos ($p = 0.015$), suggesting *that faster recruitment could be deleterious for those reassuming meiosis, yielding more abnormal karyotype*.

None of the variables studied showed *any association with the rate of embryo mosaicism*

Association of ovarian stimulation and embryonic aneuploidy in *in vitro* fertilization cycles with preimplantation genetic testing: A narrative systematic review

Jorge Rodriguez-Purata^{1,2}, Maria Jose Gomez-Cuesta¹, Enrique Cervantes-Bravo^{1,2}

¹Clinica de la Fertilidad "CdelaF", Prolongacion Vasco de Quiroga 4001, Torre A Piso 10, Colonia Santa Fe, Cuajimalpa de Morelos, 05370, Mexico City, Mexico

²Centro Medico ABC, Avenida Carlos Graef Fernández 154, Colonia Santa Fe, Cuajimalpa de Morelos, 05300, Mexico City, Mexico

- ❑ To date, it has been *impossible to isolate if the gonadotropin dosage actually distresses the oocyte or if the aneuploidy* is simply a reflection of its low quality.
- ❑ If, for a moment, we assume that COS does, in fact, impact embryonic aneuploidy, what *would it be preferable to have, a lower ratio of aneuploidy or higher total number of euploid embryos?*

Low Gonadotropin Dosage Reduces Aneuploidy in Human Preimplantation Embryos: First Clinical Study in a UAE Population

Kabir Sachdeva, Divyesh Upadhyay, Richard Discutido, Merlin Mary Varghese, Firas Albuz,
Rawan Almekosh, Linda Bouhafs, Sadika Solkar, Martina Stevikova, and Braulio Peramo

- ❑ *Gonadotropin dosage may act as a contributing factor in increasing aneuploidy incidences for the patients undergoing IVF cycles in the UAE population.*
- ❑ *This study shows that in all patient age groups, lower drug stimulation leads to an increasing trend in embryo euploidy.*

RBMO



COUNTERCURRENT

Why ovarian stimulation should be aimed to maximize oocyte yield

Baris Ata^{a,b,*}

CONCLUSION – THE MORE THE BETTER

Available evidence suggests that every oocyte contributes to CLBR and gonadotrophin stimulation is not harmful to follicle or oocyte reproductive potential.

Descriptive analysis of Rekovelle® “real-world” experience

Edson Borges Jr. Ph.D.^{a,b}, Daniela Braga, Ph.D.^{a,b}, Patricia Guilherme, M.Sc.^a, Assumptolaconelli Jr., MD.^{a,b}, Amanda Setti, M.Sc.^{a,b}

^a Fertility Medical Group, São Paulo – SP, Brazil

^b Sapientiae Institute – Centro de Estudos e Pesquisa em Reprodução Humana Assistida, São Paulo – SP, Brazil


Rekovelle: 362 ciclos / 3958 ovócitos



(submitted)


Ciclos iniciados (n=362)

Idade ♀ 37,3 ± 3,1 anos



■ Congelamento de oócitos

■ Fertilização in vitro




— Fertility — Bula Rekovelle





FERTILITY


Ciclos PGT-A (88 ciclos, 330 embriões)



Ciclos PGT-A (88 ciclos, 330 embriões)



Dose de Follitropin alfa (UI) vs. incidência de aneuploida




* Diferenças não significantes

a ≠ b


■ Euplóides ■ Aneuplóides

Dose de folitropina delta (μ g) vs. incidência de aneuploidia




FERTILITY

Resultados COS Rekovelle x Gonal




Ciclos PGT-A Rekovelle x Gonal





Resultados NGS FERTILITY

- folitropina alfa
- folitropina delta




Grupo geral (n=784 ciclos)







Subgrupo resposta ovariana




Grupo geral (n=124 ciclos)



Subgrupo idade materna



Subgrupo resposta ovariana



Take home message



MELHORES TAXAS DE EUPLOIDIA


- FOLITROPINA ALFA
doses de FSH 1.500 - 3.000 UI / idade / subresposta ovariana
- FOLITROPINA DELTA
doses de FSH 1.500 - 144 µcg / normo ou alta resposta ovariana

Diferentes gonadotropinas / Diferentes taxas de euploidia ??




Direção

Assumpto Iaconelli Jr.
Edson Borges Jr.



Laboratório de FIV

Kelly C. Pinheiro
Livia Silvia Vingris
Patrícia Guilherme
Rafaela Ferrazi Maluf
Tatiana Nunes de Melo




Laboratório de Andrologia

Rodrigo Rosa Provenza
Thais de Almeida Silva Ferreira




Pesquisa e Educação

Amanda Setti
Christina Morishima
Daniela Braga
Joana Nogueires Simas
Lorrana de Souza Anjos




Corpo Clínico

Barbara Brigati
Carla Iaconelli
Edward Carrilho
Fernanda Montenegro
Fábio Biaggioni Lopes
Graziela C. C. Carvalho
Mauro Bibancos
Natalia G. Tannous
Paula Ferreiro Vieira
Mario Firmino



Psicologia

Rose M. Melamed




Anestesiologia

Marcelo Torres e
Equipe




Nutrição

Gabriela Halpern



Enfermagem

Ana Maria Domingos França
Gabriela Lima Almeida
Larissa Rodrigues Gonçalves
Maria Regina S. da Silva
Vera Lucia Alves



Informática

Marcelo Alexandre Baptista



Farmácia

Maria das N. Fernandes



Suporte

Francilene Faustino Lopes
Francisco Junior M. Anjos
Hugo Oliveira dos Reis
Janaína Gomes Pinho da Silva
Katia Rodrigues
Leidivânia Cerqueira Alves
Leonardo S. Lopes
Lohany Gabrielly Lira
Lucácio de Souza Anjos
Marcos Vinícius de Sousa
Simone de S. Carvalho
Zenilda da Conceição Souza



Administração

Margaret Meira
Fabiana Garcia

Obrigado!


Dr. Edson Borges Jr.

www.fertility.com.br

E-mail: edson@fertility.com.br



FERTILITY
MEDICAL GROUP



FERTILITY